#Mrna vaccine spike protein dangers series
described for the first time a series of nine patients, eight of whom with arterial hypertension well controlled by treatment, who were vaccinated with Pfizer (Comirnaty) or Moderna (Spikevax). In a Research Letter published in Hypertension, Meylan et al. 2–6 COVID vaccination and arterial hypertension 1 Another possible undesirable effect recently associated with vaccination against COVID-19 seems to be the arterial hypertension, also reported so far as a relatively rare and probably transient effect. The Italian Society of Cardiology (SIC) recently published in the Italian Journal of Cardiology an ‘Expert Opinion’ on myocarditis and pericarditis associated with vaccination against COVID-19. Obviously, this is not the place to discuss the enormous benefits that COVID-19 vaccination is bringing to public health through the prevention of the most fearful complications of Sars-CoV-2 infection.įrom a cardiovascular standpoint, it is important to remember that in the summer of 2021, approximately six months after the authorization of the two mRNA vaccines by Pfizer and Moderna, the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) reported cases of myocarditis and pericarditis as potential, albeit rare, side effects of vaccination (FDA: EMA: ).īoth regulatory bodies concluded that the advantages of vaccination remain paramount over the risk of myocarditis and pericarditis, a risk that should in any case be monitored. In Italy, 48 million individuals have undergone a complete vaccination.Ĭurrently, five different vaccines are authorized in Italy: (i) Pfizer-BioNtech ‘Comirnaty’ (ii) ‘Spikevax’ by Moderna (iii) ‘Vaxzevria’ by AstraZeneca (iv) ‘Janssen’ by Johnson & Johnson (v) ‘Nuvaxovid’ by Novavax. Also worldwide, on the same date over 12 billion total doses of the vaccine were administered, of which over 136 million in Italy. Several studies have shown that post vaccine myocarditis/pericarditis are generally short-lasting phenomena with favourable clinically course.ĬOVID-19, Vaccines, Hypertension, Myocarditis, Pericarditis IntroductionĪccording to data from the World Health Organization ( ), as of confirmed cases of COVID-19 were 522 million worldwide (of which over 17 million in Italy), associated with a total number of deaths of over 6 million (165 738 in Italy). In the age group most at risk of COVID-19 vaccine myocarditis (12–29 years), for every 100 000 vaccinated, compared to about four more cases of myocarditis we have 56 fewer hospitalizations, 13.8 admissions to intensive care and 0.6 fewer deaths.
Regarding myo-pericarditis, there is evidence that the advantages of COVID-19 vaccination over non-vaccination remain preponderant in terms of prevented hospitalizations and serious complications of COVID-19, compared with the risk of developing myocarditis.
This would result in a lack of ACE 2 activity on cell surfaces and therefore a relative deficiency of angiotensin 1-7 with a relative excess of angiotensin II, which could explain, at least in part, the blood pressure increases. It is well known that the ‘spike protein’ of the Sars-CoV-2 virus, the synthesis of which is induced by vaccines, binds to ACE 2 receptors, inducing their migration towards the inside of the cell. The incidence of serious hypertensive emergencies or stage III hypertension has been reported as 0.6%.
According to some recent studies, the incidence of a significant increase in blood pressure after COVID-19 vaccination is about 3.2% (95% CI: 1.62–6.21). The proliferation of good quality observational studies on the potential adverse effects of COVID-19 vaccination has greatly increased our knowledge on myocarditis and pericarditis, and also, more recently, on arterial hypertension.
0 kommentar(er)
